Should You Buy Sarepta Therapeutics Inc (SRPT) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
Given the investor's beginner level, long-term preference, and available capital, Sarepta Therapeutics Inc (SRPT) is not a good buy at the moment. The company's financial performance is significantly deteriorating, technical indicators suggest a bearish trend, and there are no strong positive catalysts to offset the risks. The stock is better suited for investors with a higher risk tolerance or those seeking short-term speculative opportunities.
Technical Analysis
The stock is in a bearish trend with the MACD histogram negatively expanding and below 0. RSI is neutral at 42.402, and moving averages show bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels with resistance at 23.459 and support at 20.441.
Analyst Ratings and Price Target Trends
Analyst sentiment is mixed. Recent upgrades include Mizuho raising the price target to $26 and Wedbush initiating coverage with an Outperform rating and a $32 price target. However, other firms like Barclays and Baird have lowered price targets due to safety concerns and poor financial performance. The consensus view reflects uncertainty and cautious optimism.
Wall Street analysts forecast SRPT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRPT is 20.8 USD with a low forecast of 5 USD and a high forecast of 45 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast SRPT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRPT is 20.8 USD with a low forecast of 5 USD and a high forecast of 45 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 21.235
Current: 21.235
